Sotera Health/$SHC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Sotera Health

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.

Ticker

$SHC
Sector
Primary listing

Employees

3,000

Sotera Health Metrics

BasicAdvanced
$4.4B
184.76
$0.08
1.81
-

What the Analysts think about Sotera Health

Analyst ratings (Buy, Hold, Sell) for Sotera Health stock.

Bulls say / Bears say

Q2 2025 net revenues rose 6.4% year-over-year to $294 million and Adjusted EBITDA grew 9.8% to $151 million, driving management to raise full-year revenue growth outlook to 4.5–6.0% and EBITDA growth to 6.0–7.5% (Investing.com)
Sterigenics segment, the company’s largest, reported 10.5% revenue growth to $195 million in Q2 2025 on robust volume and pricing improvements, underpinning overall margin expansion (Finviz)
Nordion saw exceptional 35.6% revenue growth to $33 million in Q1 2025, driven by timing of Cobalt-60 shipments and mix improvements, highlighting strong segment momentum (TradingView)
Significant ethylene oxide litigation costs, including a $30.9 million settlement in April 2025, have increased SG&A expense by $6.2 million and created uncertainty over future reserves (Investing.com) (SEC 10-Q)
Nelson Labs segment revenues declined 9.3% in Q1 2025 to $52 million, reflecting weakening expert advisory services demand and offsetting gains elsewhere (TradingView)
Total debt remains elevated at $2.3 billion with net leverage of 3.5× in Q2 2025, limiting financial flexibility despite marginal improvement (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

Sotera Health Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sotera Health Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SHC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs